Humana Inc. (NYSE:HUM – Free Report) – Investment analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Humana in a research note issued on Tuesday, January 21st. Cantor Fitzgerald analyst S. James forecasts that the insurance provider will earn $16.17 per share for the year. Cantor Fitzgerald has a “Neutral” rating and a $395.00 price objective on the stock. The consensus estimate for Humana’s current full-year earnings is $16.11 per share.
Humana (NYSE:HUM – Get Free Report) last announced its quarterly earnings results on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.48 by $0.68. The firm had revenue of $29.30 billion for the quarter, compared to analyst estimates of $28.66 billion. Humana had a net margin of 1.18% and a return on equity of 13.20%.
Check Out Our Latest Analysis on Humana
Humana Stock Performance
NYSE:HUM opened at $284.74 on Wednesday. The firm has a market capitalization of $34.29 billion, a PE ratio of 25.22, a price-to-earnings-growth ratio of 2.13 and a beta of 0.55. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.67. Humana has a 12-month low of $213.31 and a 12-month high of $411.80. The firm has a 50-day moving average price of $273.82 and a 200 day moving average price of $306.62.
Humana Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Tuesday, December 31st will be issued a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a yield of 1.24%. The ex-dividend date of this dividend is Tuesday, December 31st. Humana’s dividend payout ratio is presently 31.36%.
Insider Buying and Selling at Humana
In other news, insider Timothy S. Huval sold 3,703 shares of the business’s stock in a transaction dated Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total transaction of $948,930.78. Following the completion of the transaction, the insider now directly owns 8,181 shares in the company, valued at approximately $2,096,463.06. The trade was a 31.16 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.29% of the company’s stock.
Institutional Inflows and Outflows
A number of institutional investors have recently bought and sold shares of HUM. State Street Corp raised its position in shares of Humana by 1.0% during the third quarter. State Street Corp now owns 5,357,420 shares of the insurance provider’s stock worth $1,701,582,000 after purchasing an additional 53,272 shares during the period. FMR LLC increased its stake in Humana by 23.4% during the 3rd quarter. FMR LLC now owns 3,388,859 shares of the insurance provider’s stock worth $1,073,387,000 after purchasing an additional 643,291 shares in the last quarter. Pzena Investment Management LLC raised its holdings in Humana by 8.1% during the 3rd quarter. Pzena Investment Management LLC now owns 2,506,250 shares of the insurance provider’s stock worth $793,830,000 after buying an additional 187,903 shares during the period. Marshall Wace LLP lifted its stake in Humana by 118.9% in the second quarter. Marshall Wace LLP now owns 1,425,302 shares of the insurance provider’s stock valued at $532,564,000 after buying an additional 774,085 shares in the last quarter. Finally, Legal & General Group Plc boosted its holdings in shares of Humana by 2.1% in the second quarter. Legal & General Group Plc now owns 1,183,985 shares of the insurance provider’s stock valued at $442,396,000 after buying an additional 24,842 shares during the period. Institutional investors and hedge funds own 92.38% of the company’s stock.
About Humana
Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Recommended Stories
- Five stocks we like better than Humana
- What is the S&P 500 and How It is Distinct from Other Indexes
- Teck Resources: America’s Ally in Rare Earth Elements
- What Does Downgrade Mean in Investing?
- Best Buy’s Dividend Is a Bargain With Double-Digit Upside
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- SAP’s Strong Momentum: A Bullish Setup for Investors
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.